Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102481 | 1.00 | TSHR (0.56) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL1953736 | 1.00 | TSHR (0.56) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| Ammonia Solution, Strong SCHEMBL28791009 | 0.97 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL10472538 | 0.85 | ALDH1A1 (0.64) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL10453248 | 0.85 | ALDH1A1 (0.64) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL606619 | 0.85 | ALDH1A1 (0.64) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL2031851 | 0.79 | TSHR (0.56) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL28116541 | 0.79 | TSHR (0.56) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL569205 | 0.76 | ALDH1A1 (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL3112519 | 0.76 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7767675-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | TSHR 1722/4885ALDH1A1 1368/4885HMGCR 4554/4885 |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | TSHR 1722/4885ALDH1A1 1368/4885HMGCR 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.